Skip to main
MDXG
MDXG logo

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc has demonstrated robust financial growth, with total revenue reported at $98.6 million for the second quarter of 2025, reflecting a year-over-year increase of approximately 13%. The strength in MiMedx's wound-care and surgical segments is particularly notable, as the wound portfolio grew by 12% to $64.5 million, while surgical product sales surged by 15% to reach $34.1 million. Additionally, the company has revised its revenue estimate for 2025 to $387.3 million, an increase from the previous projection, indicating confidence in continued operational success and market demand.

Bears say

MiMedx Group Inc has experienced a decline in its gross margin, dropping to approximately 81% from 83% in the previous quarter, primarily attributed to production variances and changes in product mix. The company has committed to a long-term outlook of achieving low double-digit percentage year-over-year revenue growth along with an adjusted EBITDA margin exceeding 20%. However, the potential for adverse changes in reimbursement rates set by CMS poses a significant risk to MiMedx's financial performance and overall business viability.

MiMedx Group (MDXG) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 1 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.